JP2002506034A5 - - Google Patents

Download PDF

Info

Publication number
JP2002506034A5
JP2002506034A5 JP2000535346A JP2000535346A JP2002506034A5 JP 2002506034 A5 JP2002506034 A5 JP 2002506034A5 JP 2000535346 A JP2000535346 A JP 2000535346A JP 2000535346 A JP2000535346 A JP 2000535346A JP 2002506034 A5 JP2002506034 A5 JP 2002506034A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000535346A
Other languages
Japanese (ja)
Other versions
JP2002506034A (ja
JP3877961B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1999/001496 external-priority patent/WO1999045931A1/en
Publication of JP2002506034A publication Critical patent/JP2002506034A/ja
Publication of JP2002506034A5 publication Critical patent/JP2002506034A5/ja
Application granted granted Critical
Publication of JP3877961B2 publication Critical patent/JP3877961B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000535346A 1998-03-11 1999-03-10 Cns疾患の治療におけるエピアロプレグナノロン Expired - Fee Related JP3877961B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3786998A 1998-03-11 1998-03-11
US09/037,869 1998-03-11
PCT/EP1999/001496 WO1999045931A1 (en) 1998-03-11 1999-03-10 Epiallopregnanolone in the treatment of cns disorders

Publications (3)

Publication Number Publication Date
JP2002506034A JP2002506034A (ja) 2002-02-26
JP2002506034A5 true JP2002506034A5 (cg-RX-API-DMAC7.html) 2005-11-17
JP3877961B2 JP3877961B2 (ja) 2007-02-07

Family

ID=21896803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000535346A Expired - Fee Related JP3877961B2 (ja) 1998-03-11 1999-03-10 Cns疾患の治療におけるエピアロプレグナノロン

Country Status (9)

Country Link
US (1) US6455516B1 (cg-RX-API-DMAC7.html)
EP (1) EP1063999B1 (cg-RX-API-DMAC7.html)
JP (1) JP3877961B2 (cg-RX-API-DMAC7.html)
CN (1) CN1270718C (cg-RX-API-DMAC7.html)
AT (1) ATE307592T1 (cg-RX-API-DMAC7.html)
AU (1) AU756001B2 (cg-RX-API-DMAC7.html)
CA (1) CA2321728C (cg-RX-API-DMAC7.html)
DE (1) DE69927960T2 (cg-RX-API-DMAC7.html)
WO (1) WO1999045931A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
DK1812009T3 (da) * 2004-11-18 2013-08-05 Umecrine Ab GABA-steroidantagonister og deres anvendelse til behandling af CNS-lidelser
RU2413516C2 (ru) * 2004-11-18 2011-03-10 Умекрин Аб Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
EP2711372A1 (en) 2006-11-21 2014-03-26 Umecrine AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders
EP2167098B1 (en) * 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
US20100204192A1 (en) 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
JP5687287B2 (ja) * 2010-01-14 2015-03-18 ウメクライン ムード エービー 改善された保存性及び溶解特性を有する3−ベータ−ヒドロキシ−5−アルファ−プレグナン−20−オンを含有する薬学的組成物
CN106983754A (zh) 2011-05-20 2017-07-28 国家医疗保健研究所 Cb1受体拮抗剂
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
RU2667065C2 (ru) 2012-11-28 2018-09-14 Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) Производные прегненолона
US20150313915A1 (en) * 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
CN106163528A (zh) 2014-01-29 2016-11-23 梅克芳识别有限公司 用于治疗肝脑病的甾族化合物
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) * 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ab公司 新穎化合物
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
US10933014B2 (en) 2017-01-09 2021-03-02 Asarina Pharma Ab Injectable suspension comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, and a method for the manufacturing thereof
CN110430883A (zh) 2017-02-10 2019-11-08 阿沙里那制药公司 用于医学治疗的3β-羟基-5α-孕烷-20-酮
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
US20210228596A1 (en) * 2017-10-12 2021-07-29 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
CN111918657A (zh) 2018-04-05 2020-11-10 阿沙里那制药有限公司 用于治疗物质戒断障碍的gaba-a拮抗剂
US20240383942A1 (en) 2021-09-14 2024-11-21 Nanjing Minova Pharmaceutical Co., Ltd. Water-soluble allopregnanolone derivative, and preparation method therefor and use thereof
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
WO2023083978A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083979A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
CN1254283A (zh) * 1997-05-02 2000-05-24 美国家用产品公司 孕烷-3-醇-20-酮

Similar Documents

Publication Publication Date Title
BE2018C020I2 (cg-RX-API-DMAC7.html)
BE2015C057I2 (cg-RX-API-DMAC7.html)
BE2016C007I2 (cg-RX-API-DMAC7.html)
BE2015C018I2 (cg-RX-API-DMAC7.html)
BE2013C051I2 (cg-RX-API-DMAC7.html)
BE2013C020I2 (cg-RX-API-DMAC7.html)
BE2013C001I2 (cg-RX-API-DMAC7.html)
BE2012C036I2 (cg-RX-API-DMAC7.html)
BE1025464I2 (cg-RX-API-DMAC7.html)
BE2008C046I2 (cg-RX-API-DMAC7.html)
BE2010C011I2 (cg-RX-API-DMAC7.html)
BRPI0017527B8 (cg-RX-API-DMAC7.html)
IN2005MU00808A (cg-RX-API-DMAC7.html)
BE2008C047I2 (cg-RX-API-DMAC7.html)
BE2011C004I2 (cg-RX-API-DMAC7.html)
BRPI0001672A2 (cg-RX-API-DMAC7.html)
JP2002526290A5 (cg-RX-API-DMAC7.html)
JP2002532924A5 (cg-RX-API-DMAC7.html)
BRPI0012675B8 (cg-RX-API-DMAC7.html)
JP2002518404A5 (cg-RX-API-DMAC7.html)
BRPI0017522A2 (cg-RX-API-DMAC7.html)
JP2000113644A5 (cg-RX-API-DMAC7.html)
BRMU7902607U2 (cg-RX-API-DMAC7.html)
BRPI0303609A (cg-RX-API-DMAC7.html)
FR2773081A3 (cg-RX-API-DMAC7.html)